Greg is a bona-fide expert in the medical device space, having worked in the healthcare industry since 1983 forming numerous successful healthcare partnerships among physicians , healthcare facilities and providers of high technology medical equipment, and patient treatment facilities. He previously served as a Business Development Consultant at 21st Century Oncology from 2001 thru 2017 , once the largest radiology provider in the world, with over 168 facilities offering cancer care services across multiple cancer care modalities Greg has been the President of Biotechnology Integration and Management, LLC which is a healthcare consulting firm that he founded in 2000. He became involved with Iylon as he is a long-standing client of the healthcare group of Adler Pollock & Sheehan PC, where John Tarantino serves as President Emeritus. He has collaborated with the firm many times, successfully securing a groundbreaking 5 Certificates of Need to establish radiation therapy centers in joint ventures with Rhode Island’s three major hospital systems that utilize photon radiotherapy. He also is the founding member of Rhode Island PET/CT Mobile Imaging Network ,(“RIPET”) , which he has been an owner and Board member since he secured a Certificate of Need to establish a mobile PET/CT Network in 2002 .Since that time , RIPET has provided cancer staging imaging services for over 20,000 patients in the state of Rhode Island. Greg’s professional and personal experience of 30 years in creating and facilitating successful partnerships has taught him that cancer care should best be provided through a “comprehensive coordinated continuum of care” model that is customized and personalized to effectively treat the patient’s specific type of cancer but also preserves the patient’s quality of life . In this manner if a patient can’t be cured their treatment can be tailored in a manner that will provide the patient with the ability to live with cancer as a chronic illness no different than if they had heart disease, high blood pressure or diabetes . Through such a model a patient is assured that they will not only receive the correct customized and personalized cancer care modalities but will receive them in the order that best provides for the greatest tumoricidal effect with the least possible side effects and resultant co – morbidities. This is what Iylon's Precision personalized cancer care was created to achieve and is why Greg enthusiastically has joined Iylons Sr Management team to contribute his passion to Iylon's mission of educating hospitals, patients, and oncologists alike on the features advantages and benefits of Iylon’s treatment paradigm and customized personalized treatment protocols .